Literature DB >> 327532

Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study.

K Schimpf, B Fischer, P Rothmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 327532     DOI： 10.1111/j.1600-0609.1977.tb01528.x

Source DB:  PubMed          Journal:  Scand J Haematol Suppl        ISSN： 0080-6722


× No keyword cloud information.
  6 in total

1.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

Authors:  Omotola O Olasupo; Megan S Lowe; Ashma Krishan; Peter Collins; Alfonso Iorio; Davide Matino
Journal:  Cochrane Database Syst Rev       Date:  2021-08-18

4.  Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.

Authors:  Byung Suk Moon; Jun Seok Choi; Chur Woo You
Journal:  Korean J Pediatr       Date:  2013-07-19

5.  Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China.

Authors:  Congling Gu; Hui Huang; Yi Han
Journal:  Adv Ther       Date:  2022-06-30       Impact factor: 4.070

Review 6.  Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.

Authors:  Erik Berntorp; Gerald Spotts; Lisa Patrone; Bruce M Ewenstein
Journal:  Biologics       Date:  2014-04-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.